# Bioequivalence Study of Sulfadoxine/Pyrimethamine 500/25 mg Dispersible Tablet

> **NCT06522763** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Swiss Pharma Nigeria Limited** · enrollment: 46 (estimated)

## Conditions studied

- Fasting

## Interventions

- **DRUG:** Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets.
- **DRUG:** Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ

## Key facts

- **NCT ID:** NCT06522763
- **Lead sponsor:** Swiss Pharma Nigeria Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2024-08
- **Final completion:** 2024-09
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2024-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06522763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06522763, "Bioequivalence Study of Sulfadoxine/Pyrimethamine 500/25 mg Dispersible Tablet". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06522763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*